Understanding Bone Fracture Risk in Prostate Cancer Patients on Androgen Blockade Therapy
Prostate cancer is one of the most common cancers in men. When the disease progresses, doctors often prescribe hormone-based therapies that target the androgens fueling tumor growth. One common approach is maximal androgen blockade (MAB)—combining traditional androgen deprivation therapy (ADT) with drugs that block androgen receptor signaling. These add-on medications include abiraterone acetate, enzalutamide, apalutamide, and darolutamide. Some patients also receive older anti-androgens like flutamide, bicalutamide, or nilutamide.
A systematic review and meta-analysis published in early 2026 in Prostate Cancer and Prostatic Diseases asked a straightforward question: does adding these androgen receptor pathway inhibitors to standard hormone therapy increase fracture risk? The research team analyzed 17 clinical trials with more than 16,000 patients to find out.
The Numbers Behind the Problem
Prostate cancer and its treatments already strain bone health. ADT reduces testosterone, which slows cancer growth but also weakens bones over time. Men on these therapies face higher fracture risks than men without cancer. When physicians layer additional anti-androgen medications onto ADT—creating MAB—the hormonal environment changes even more dramatically.
The research team searched PubMed/Medline and the Cochrane Library for clinical trials comparing MAB regimens against ADT alone. They included 17 randomized controlled trials with 16,162 participants: 9,240 received MAB and 6,922 received ADT monotherapy.
What the Data Revealed
The findings were consistent and noteworthy. Across all androgen receptor pathway inhibitors—abiraterone, enzalutamide, apalutamide, and darolutamide—patients receiving MAB had significantly higher fracture rates than those on ADT alone. The pooled odds ratios ranged from 1.5 to 2.4. Patients on combined therapy were 50% to 140% more likely to experience fractures than those on single-agent treatment.
The magnitude of increased risk did not differ substantially between individual drugs. Whether patients took abiraterone or enzalutamide, the fracture risk climbed by similar amounts. The risk seems to stem from the overall androgen suppression strategy rather than any specific medication.
The analysis also looked at bone protective agents—medications like denosumab and zoledronic acid that can strengthen bone and reduce fracture risk. Only 7 of the 17 studies reported data on BPA use, making it difficult to assess how effectively these protective agents were being deployed in clinical practice. This reporting gap means actual fracture rates might underestimate the protective benefit achievable with proper BPA implementation.
Why Bones Suffer During Hormone Therapy
Understanding why fractures become more likely requires a quick look at how testosterone affects skeletal health. Male sex hormones support bone maintenance by promoting osteoblast activity (cells that build bone) and limiting osteoclast function (cells that break bone down). When ADT suppresses these hormones, the balance shifts toward bone loss. Bone mineral density can decline by 2-6% annually during the first few years of therapy, particularly affecting the spine and hip.
Adding a second androgen-blocking agent intensifies this hormonal withdrawal. The combination creates a state of near-complete androgen deficiency, which accelerates bone resorption and compromises bone microarchitecture.
Clinical Implications
The study’s results carry important implications. First, clinicians prescribing MAB should assess fracture risk before and during therapy. Standard tools like FRAX can help quantify baseline risk, taking into account age, weight, smoking status, prior fractures, family history, and other factors.
Second, bone protective agents deserve serious consideration for appropriate candidates. Current guidelines from ESMO, EAU, and NCCN already recommend bone health interventions for certain patients on ADT. The new meta-analysis strengthens the case for extending these protections to MAB recipients.
Third, BPA use should be individualized. Not every patient needs these medications, and they carry their own risks and costs. Zoledronic acid given annually can reduce vertebral fracture rates but may cause flu-like symptoms, jawbone complications in rare cases, and kidney function concerns. Denosumab, administered as a subcutaneous injection every six months, offers an alternative with different side effect profiles.
Practical Questions
How long does increased fracture risk persist after starting MAB? The clinical trials followed patients for varying durations, making it difficult to pinpoint when risk peaks or whether it plateaus. Most bone density loss occurs within the first two to three years of hormone therapy, with fractures typically occurring later.
Should patients on MAB undergo regular bone density testing? Many experts recommend baseline DEXA scans at treatment initiation with follow-up scans every one to two years for patients on prolonged hormone therapy. Those with osteopenia or osteoporosis may need more frequent monitoring.
What about lifestyle modifications? Weight-bearing exercise, adequate calcium and vitamin D intake, smoking cessation, and limiting alcohol consumption all support skeletal health. These interventions cannot replace medical therapy for high-risk patients but can amplify the benefits of bone protective agents.
The Bottom Line
The 2026 meta-analysis provides compelling evidence that healthcare providers should not overlook bone health when prescribing maximal androgen blockade. The survival benefits of these regimens are well-established for appropriate prostate cancer patients, but optimizing care means addressing both cancer control and quality-of-life concerns—including fracture prevention.
FAQ: Bone Fracture Risk and Androgen Blockade Therapy
Q: What is maximal androgen blockade (MAB)?
A: Maximal androgen blockade combines traditional androgen deprivation therapy (which suppresses testicular testosterone production) with an additional androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach more completely blocks the androgens that fuel prostate cancer growth. Some regimens also include older anti-androgens like flutamide, bicalutamide, or nilutamide.
Q: How much does MAB increase fracture risk compared to ADT alone?
A: The meta-analysis found that MAB increases fracture risk by 50% to 140% compared to ADT monotherapy. The pooled odds ratios ranged from 1.5 to 2.4 across different androgen receptor pathway inhibitors, indicating a significant elevation in risk regardless of which specific drug was added.
Q: Which medications used in MAB were studied?
A: The meta-analysis examined abiraterone acetate, enzalutamide, apalutamide, and darolutamide—all FDA-approved androgen receptor pathway inhibitors commonly used with ADT for advanced prostate cancer. All four drugs showed similar fracture risk increases.
Q: What are bone protective agents (BPAs)?
A: Bone protective agents are medications that strengthen bone and reduce fracture risk. For prostate cancer patients on hormone therapy, commonly used options include zoledronic acid (a bisphosphonate given as an annual intravenous infusion) and denosumab (a RANKL inhibitor administered as a twice-yearly subcutaneous injection).
Q: Who should receive bone protective agents while on MAB?
A: Current guidelines recommend considering BPAs for patients at high fracture risk, including those with osteoporosis, osteopenia with additional risk factors, advanced age, low body weight, history of fragility fractures, or prolonged anticipated duration of hormone therapy. Patients should discuss their specific risk profile with their oncology team.
Q: Does stopping MAB reduce fracture risk?
A: Bone density typically improves after stopping hormone therapy, but recovery takes time—often several months to years. Abruptly stopping effective cancer treatment to protect bones is generally not advisable. Patients should work with their physicians to balance cancer control against skeletal health.
Q: What monitoring is recommended for patients on MAB?
A: Baseline bone mineral density testing (DEXA scan) before starting MAB is advisable for most patients. Follow-up DEXA scans every one to two years allow clinicians to track bone changes and intervene if loss accelerates.
Q: Are there medications that do not increase fracture risk as much?
A: The meta-analysis found no significant differences between different androgen receptor pathway inhibitors. All agents in this class appear to carry similar skeletal effects when added to ADT. Duration and intensity of androgen suppression—rather than specific drug choice—seems to drive the increased risk.
Q: Can lifestyle changes help reduce fracture risk during MAB?
A: Yes. Weight-bearing exercises, adequate dietary calcium (1000-1200 mg daily), sufficient vitamin D (800-2000 IU daily), smoking cessation, limiting alcohol, and fall prevention all support bone health. These changes complement but do not replace medical therapy for high-risk individuals.
Q: What should patients discuss with their healthcare providers?
A: Patients beginning MAB should ask about their baseline fracture risk, whether bone density testing is warranted, if bone protective agents are appropriate, optimal calcium and vitamin D intake, safe exercise options, and warning signs of fractures. Shared decision-making between patients and clinicians can optimize outcomes for both cancer control and skeletal health.
